Bohrane Slama

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

Frédérik Damm, Olivier Kosmider, Véronique Gelsi‐Boyer et al. · Blood · 2012 · 231 citations

Life Sciences, Molecular Biology, Molecular Genetics +16

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Uwe Platzbecker, Argiris Symeonidis, Esther Natalie Olíva et al. · Leukemia · 2017 · 130 citations · Full text

Medicine, Hematology, Pharmacology +13

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret et al. · Leukemia · 2015 · 121 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study

Brigitte Pegourié, Lionel Karlin, Lotfi Benboubker et al. · American Journal of Hematology · 2019 · 58 citations

Medicine, Pharmacology, Pharmacotherapy +17

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

Charikleia Kelaïdi, Odile Beyne‐Rauzy, Thorsten Braun et al. · Annals of Hematology · 2013 · 48 citations

Medicine, Pharmacotherapy, Exercise Physiology +10